Closely-held ZappRx closed a $25-million Series B funding led by Qiming US Healthcare Fund, with participation from SR One, which led ZappRx’s Series A round in 2014, and GV, formerly Google Ventures.
ZappRx is a digital health company focused on modernizing and expediting the specialty drug prescribing process. As part of the financing, Mark McDade, managing partner at Qiming US, will join ZappRx’s board.
Proceeds will be used to build ZappRx’s team, drive provider adoption nationwide and accelerate growth.
“ZappRx has created a unified platform that we believe will dramatically transform the ecosystem experience around specialty drugs to benefit providers, payers, pharmacists, patients, and biopharma manufacturers,” Mr. McDade, said in a statement.
